Dark

Check out our API

AZYO
Aziyo Biologics, Inc. Class A Common Stock
stock NASDAQ

Inactive

Sep 6, 2023

1.49USD+2.055%(+0.03)8,103

Pre-market

0.00USD-100.000%(-1.46)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 27, 2021

04:01PM EST Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that members of management will present at the upcoming H.C. Wainwright Bioconnect Virtual Conference. GlobeNewswire Inc

Dec 10, 2021

04:27PM EST Aziyo Biologics Files Form4 Filing Showing Director Kevin Rakin Buys ~412K Shares At Average $4.24/Share Benzinga

Dec 8, 2021

05:31PM EST Aziyo Biologics Announces Closing of $14.0 Million Private Placement GlobeNewswire Inc

Dec 6, 2021

07:02AM EST Aziyo Biologics Announces $14M Private Placement at $4.24/Share Benzinga

06:59AM EST Aziyo Biologics, Inc. (the Company) today announced that it has entered into a definitive agreement to sell securities in a private placement that is expected to result in gross proceeds to the Company of approximately $14.0 million, before deducting offering expenses. GlobeNewswire Inc

Nov 15, 2021

04:05PM EST Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the company will participate in two upcoming virtual investor conferences. GlobeNewswire Inc

Nov 9, 2021

05:04PM EST Aziyo Biologics Sees FY21 Sales $47M-$48M Vs. $48.72M Est. Benzinga

05:04PM EST Aziyo Biologics Q3 EPS $(0.81) Misses $(0.62) Estimate, Sales $11.48M Beat $11.48M Estimate Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

Oct 26, 2021

08:36AM EDT The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children Benzinga

Oct 25, 2021

04:02PM EDT Aziyo Biologics Sees FY21 Revs ~$11.5M Vs $11.48M Est. Benzinga

04:01PM EDT Aziyo Biologics Provides Business Update and Preliminary Third GlobeNewswire Inc

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 29, 2021

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

Sep 20, 2021

11:02AM EDT Aziyo Biologics Earnings Perspective: Return On Capital Employed Benzinga

Sep 15, 2021

04:05PM EDT Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming 2021 Cantor Global Healthcare Conference. GlobeNewswire Inc

Aug 31, 2021

04:05PM EDT Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the appointment of Peter G. Edwards as General Counsel. GlobeNewswire Inc

Aug 9, 2021

04:13PM EDT Aziyo Biologics Sees Q3 Sales $11M-$12M Vs. $11.76M Est Benzinga

04:11PM EDT Aziyo Biologics Q2 EPS $(0.23) Beats $(0.53) Estimate, Sales $12.20M Beat $12.04M Estimate Benzinga

04:01PM EDT Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three and six months ended June 30, 2021. GlobeNewswire Inc

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 26, 2021

04:01PM EDT Aziyo Biologics to Report Second Quarter 2021 Financial Results on GlobeNewswire Inc

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 13, 2021

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jun 9, 2021

10:40AM EDT Endurant Capital Management Reports In 13G Filing A 12.31% Stake In Aziyo Biologics; Raises Stake From ~408K Shares To ~873K Shares Benzinga

Jun 7, 2021

08:00AM EDT Aziyo Biologics, Inc. (Nasdaq: AZYO) on June 2, 2021 issued a voluntary recall pertaining to a single donor lot of its FiberCel Fiber Viable Bone Matrix, a bone repair product made from human tissue that is used in various orthopedic and spinal procedures. GlobeNewswire Inc

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

04:17PM EDT Aziyo Biologics Q1 EPS $(0.50) Beats $(0.57) Estimate, Sales $12.90M Beat $11.18M Estimate Benzinga

04:05PM EDT Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three months ended March 31, 2021. GlobeNewswire Inc

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 30, 2021

07:31AM EDT The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs Benzinga

Apr 28, 2021

04:34PM EDT Aziyo Biologics Announces Initiation of De Novo CanGaroo Clinical Study Benzinga

04:05PM EDT Aziyo Biologics Announces Initiation of De Novo CanGaroo Clinical GlobeNewswire Inc

Apr 26, 2021

04:05PM EDT Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Truist Securities Life Sciences Summit. GlobeNewswire Inc

Apr 20, 2021

04:05PM EDT Aziyo Biologics to Report First Quarter 2021 Financial Results on GlobeNewswire Inc

Mar 1, 2021

04:23PM EST Aziyo Biologics Sees FY21 Sales $50M-$52M Vs. $50.81M Est. Benzinga

04:22PM EST Aziyo Biologics Q4 EPS $(0.57) Misses $(0.50) Estimate, Sales $12.47M Beat $11.64M Estimate Benzinga

04:05PM EST Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the fourth quarter and full year ended December 31, 2020. GlobeNewswire Inc

03:51AM EST Earnings Scheduled For March 1, 2021 Benzinga

Feb 18, 2021

04:05PM EST Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Cowen 41st Annual Health Care Conference. GlobeNewswire Inc

Feb 17, 2021

04:08PM EST Aziyo Biologics Announces First Patient Enrolled In HEAL Study Benzinga

Feb 15, 2021

12:00PM EST Aziyo Biologics to Report Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Feb 11, 2021

04:23PM EST Aziyo Biologics Announces Product Design Completion For Its CanGaroo Envelope For Implantable Electronic Devices Benzinga

04:05PM EST Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today product design completion for CanGaroo with antibiotics, the next generation of the Companys CanGaroo Envelope. GlobeNewswire Inc

Jan 28, 2021

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

Jan 12, 2021

09:00AM EST Surgalign Holdings Announce the Commercial Launch of GlobeNewswire Inc

Nov 19, 2020

04:09PM EST Aziyo Biologics Q3 EPS $(15.79) Down From $(4.81) YoY, Sales $11.80M Beat $11.21M Estimate Benzinga

04:05PM EST Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three and nine months ended September 30, 2020. GlobeNewswire Inc

04:24AM EST Earnings Scheduled For November 19, 2020 Benzinga

Nov 17, 2020

04:05PM EST Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Piper Virtual Healthcare Conference. GlobeNewswire Inc

Nov 16, 2020

04:08PM EST Surgalign Holdings And Aziyo Biologics Announce Expanded Distribution Agreement Benzinga

04:05PM EST Surgalign Holdings and Aziyo Biologics Announce Expanded GlobeNewswire Inc

Nov 12, 2020

04:27PM EST Aziyo Biologics Awarded Breakthrough Technology Contract With Premier Inc., No Terms Disclosed Benzinga

04:05PM EST Aziyo Biologics Awarded Breakthrough Technology Contract with GlobeNewswire Inc

Nov 11, 2020

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

Nov 2, 2020

09:56AM EST Benzinga's Top Upgrades, Downgrades For November 2, 2020 Benzinga

07:25AM EST Truist Securities Initiates Coverage On Aziyo Biologics with Buy Rating, Announces Price Target of $20 Benzinga

07:24AM EST Cowen & Co. Initiates Coverage On Aziyo Biologics with Outperform Rating, Announces Price Target of $20 Benzinga

07:23AM EST Cantor Fitzgerald Initiates Coverage On Aziyo Biologics with Overweight Rating, Announces Price Target of $20 Benzinga

06:06AM EST Piper Sandler Initiates Coverage On Aziyo Biologics with Overweight Rating, Announces Price Target of $20 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 30, 2020

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

Oct 22, 2020

07:52AM EDT The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat Benzinga

Oct 9, 2020

10:03AM EDT FuboTV Uplisting, Kronos Bio Highlight This Week's IPOs Benzinga

Oct 8, 2020

10:48AM EDT Azyio Biologics Shares Open For Trade At $17.32; IPO Priced At $17/Share Benzinga

09:57AM EDT Azyio Biologics Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDIT, IPO Priced At $17.00/Share Benzinga

Oct 7, 2020

08:52PM EDT Aziyo Biologics Announces Pricing of Initial Public Offering GlobeNewswire Inc

Oct 6, 2020

08:11AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Oct. 6, 2020: DPZ, AZYO, OGEN, ALKS, AN Benzinga

Sep 28, 2020

05:16PM EDT Aziyo Biologics, Inc. (Aziyo), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today that Matthew Ferguson has been appointed Chief Financial Officer (CFO), effective immediately. GlobeNewswire Inc

Sep 21, 2020

04:05PM EDT Aziyo Biologics Announces New Appointments to Board of Directors GlobeNewswire Inc

Share